Safety and Effectiveness of Concomitant iGlarLixi and SGLT-2i Use in People with T2D During Ramadan Fasting: A SoliRam Study Sub-analysis
Concomitant iGlarLixi and SGLT-2i therapy with or without other OADs was demonstrated to be safe in adults with T2D during Ramadan fast, with a low risk of hypoglycemia and improvements in glycemic outcomes.
Authors
- Saud Al Sifri
- Inass Shaltout (ORCID: https://orcid.org/0000-0003-1264-4922)
- Rakesh Sahay (ORCID: https://orcid.org/0000-0002-5471-0695)
- Mehmet Akif Büyükbeşe (ORCID: https://orcid.org/0009-0008-5255-2073)
- Lydie Melas‐Melt (ORCID: https://orcid.org/0000-0001-9698-8196)
- Mohamed Hassanein (ORCID: https://orcid.org/0000-0001-6598-6972)
- Khier Djaballah
- Rachid Malek (ORCID: https://orcid.org/0000-0002-3360-8528)
Institutions
- Cairo University (EG)
- Rashid Hospital (AE)
- Dubai Hospital (AE)
- Sanofi (France) (FR)
- Gaziantep Children's Hospital (TR)
- Centre Hospito Universitaire de Sétif (DZ)
- Mohammed Bin Rashid University of Medicine and Health Sciences (AE)
- Armed Forces Hospital (SA)
- Arysta LifeScience (France) (FR)
- Gaziantep University (TR)
- Osmania Medical College (IN)
Publication Details
- Journal
- Diabetes Therapy
- Published
- 2024-09-09
- DOI
- https://doi.org/10.1007/s13300-024-01642-2
- Citations
- 8
- Primary Topic
- Dietary Effects on Health
- Type
- article
- Field-Weighted Citation Impact
- 2.61
Funders
- Sanofi